Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899082 | 1.00 | NPC1 (0.61) | NPC1RAB9AATMJAK2TYK2 | |
| SCHEMBL2783145 | 0.86 | NPC1 (0.68) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL29899004 | 0.85 | MAPK8 (0.62) | NPC1RAB9AGRM5MAPK8MAPK10 | |
| SCHEMBL23410523 | 0.85 | MAPK8 (0.62) | NPC1RAB9AGRM5MAPK8MAPK10 | |
| SCHEMBL29899009 | 0.84 | HTR1F (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL23410295 | 0.84 | HTR1F (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29083781 | 0.84 | RAB9A (0.58) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL16974225 | 0.84 | MEN1 (0.62) | NPC1RAB9AGRM5MEN1KMT2A | |
| SCHEMBL30565890 | 0.84 | MEN1 (0.62) | NPC1RAB9AGRM5MEN1KMT2A | |
| SCHEMBL29083770 | 0.84 | IDE (0.58) | NPC1RAB9AATMGRM5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-115151257-B | Novel compounds for the treatment of diseases associated with DUX4 expression | 因维戈疗法有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4065110-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151257-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| CN-113735850-A | Synthesis method of 1,2, 4-triazole compound | 河南师范大学 | 2021-12-03 | — | — | CN | disclosed |
| WO-2021105481-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-01-28 | — | — | US | disclosed |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9884867-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-06 | — | — | US | disclosed |
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-11 | — | — | US | disclosed |
| EP-3052501-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050505-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | NPC1 1965/4885RAB9A 2770/4885ATM 439/4885 |
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | NPC1 2820/4885RAB9A 2817/4885ATM 264/4885 |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | MAPKAPK2, MAP4K2, MKNK2 | NPC1 2940/4885RAB9A 2877/4885ATM 275/4885 |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | NPC1 2820/4885RAB9A 2817/4885ATM 264/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | NPC1 3212/4885RAB9A 1291/4885ATM 4021/4885 |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | NPC1 2644/4885RAB9A 827/4885ATM 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.